stockrowGenmab A/S Sponsored ADR
GMAB Healthcare Biotechnology
Genmab A/S Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 19.2% from fiscal 2024.
- Revenue
- +24.9%
- EPS
- −9.26%
- Free cash flow
- −7.69%
Quarter to June 2026, against a year earlier
Follow GMAB
Alert me
Genmab A/S Sponsored ADR (GMAB) Gross margin
Genmab A/S Sponsored ADR's gross margin over the twelve months to 30 June 2026 was 93.0%, down 0.6 percentage points from fiscal 2025 (93.6%). Over the past ten years it has ranged from 0.00% (fiscal 2017) to 100.0% (fiscal 2022); the current reading is higher than 30% of that period. That is above the Biotechnology industry median of 65.2% and above the Healthcare sector median of 53.9%.
Gross margin, annual
Embed this chart
Annual newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| FY2025 | 93.6% | (1.82) |
| FY2024 | 95.4% | (3.21) |
| FY2023 | 98.6% | (1.37) |
| FY2022 | 100.0% | 0.00 |
| FY2021 | 100.0% | 0.00 |
| FY2020 | 100.0% | 0.00 |
| FY2019 | 100.0% | 0.00 |
| FY2018 | 100.0% | 100.00 |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | — |
Quarterly newest first
| Period | Gross margin | Change (points) |
|---|---|---|
| Jun 2026 | 92.7% | (0.02) |
| Mar 2026 | 92.8% | 0.41 |
| Dec 2025 | 92.3% | (1.98) |
| Sep 2025 | 94.3% | 0.48 |
| 27 more quarters | Free account |
Against its own ten years
Gross margin against peers
| Company | Gross margin |
|---|---|
| RPRX Royalty Pharma PLC compare | 100.0% |
| RVMD Revolution Medicines, Inc. compare | 95.6% |
| GMAB Genmab A/S Sponsored ADR | 93.0% |
| INCY Incyte Corporation compare | 92.7% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 89.4% |
| INSM Insmed, Inc. compare | 84.4% |
| ROIV Roivant Sciences Ltd. compare | 81.2% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 77.3% |
| BNTX BioNTech SE Sponsored ADR compare | 74.6% |
| Biotechnology industry median | 65.2% |
| Healthcare sector median | 53.9% |
| Market median | 45.1% |
What Gross margin is
Gross Margin tells an investor how much of each sale a company keeps after paying the direct costs of making or buying what it sells.
Gross Profit ÷ Revenue
More on GMAB
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement